富祥药业(300497) - 2025 Q3 - 季度财报

Financial Performance - The company's revenue for the third quarter was ¥254,677,075.45, a decrease of 13.51% compared to the same period last year[4] - The net profit attributable to shareholders was -¥55,840,375.42, down 40.96% year-on-year[4] - The net cash flow from operating activities was ¥28,885,723.09, reflecting a significant decline of 80.79% compared to the previous year[4] - Total operating revenue for the current period was CNY 769,351,135.51, a decrease from CNY 976,875,468.35 in the previous period, indicating a decline of approximately 21.2%[24] - Net profit for the current period was approximately -¥67.68 million, compared to -¥69.21 million in the previous period, showing an improvement of about 2.2%[26] - The company's basic earnings per share were -¥0.10, a decrease of 42.86% year-on-year[4] - The basic and diluted earnings per share remained at -¥0.12, unchanged from the previous period[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,437,899,038.97, a decrease of 2.18% from the end of the previous year[4] - The company's total current assets decreased from CNY 1,681,023,406.22 to CNY 1,524,371,914.03, a reduction of about 9.3%[20] - The company's total liabilities decreased from CNY 2,359,938,793.22 to CNY 2,269,949,195.38, reflecting a decline of approximately 3.8%[22] - The company's long-term borrowings increased from CNY 736,484,000.00 to CNY 829,474,000.00, an increase of about 12.6%[22] - The company's retained earnings decreased from CNY 264,515,944.43 to CNY 201,764,418.36, a decline of approximately 23.7%[22] Cash Flow - The company's cash and cash equivalents decreased from CNY 695,350,502.08 to CNY 632,736,892.59, a drop of about 9.0%[20] - Cash flow from operating activities generated a net amount of ¥28.89 million, down from ¥150.36 million in the previous period, indicating a decline of approximately 80.8%[28] - Cash flow from investing activities resulted in a net outflow of approximately -¥192.72 million, compared to -¥131.58 million in the previous period, reflecting an increase in outflow of about 46.5%[29] - Cash flow from financing activities yielded a net inflow of ¥157.11 million, contrasting with a net outflow of -¥13.25 million in the previous period, marking a significant turnaround[30] - The net cash and cash equivalents at the end of the period stood at ¥542.60 million, a decrease from ¥589.84 million, reflecting a decline of about 8%[30] Shareholder Information - The total number of common shareholders at the end of the reporting period is 20,651[11] - The largest shareholder, Bao Jianhua, holds 20.12% of shares, totaling 108,399,908 shares, with 59,850,000 shares pledged[11] - The second-largest shareholder, Yu Wenjun, holds 2.45% of shares, totaling 13,216,446 shares[11] - The total number of restricted shares at the end of the period is 97,806,247, with 2,574,362 shares released during the period[14] - The company has a total of 99,439,568 restricted shares at the beginning of the period[14] - The top ten shareholders collectively hold significant stakes, with the largest holding being over 20%[11] - The total number of shares held by the top ten unrestricted shareholders is 69,000,000[12] - The company has a diverse shareholder base, including both individual and institutional investors[11] - There are no changes reported in the lending or borrowing of shares among the top shareholders[12] - The company has a strategy for unlocking 25% of restricted shares annually based on the previous year's holdings[14] Business Development - The company established WeiRan International Industrial Co., Ltd. in Singapore and WeiRan Business Alliance (Shanghai) Food Technology Co., Ltd. in Shanghai to expand its international business in new protein[15] - The company has received a fertilizer registration certificate for its amino acid water-soluble fertilizer, allowing it to be marketed domestically, which is expected to become a new profit growth point[17] - The company obtained a Korean invention patent for the application of short-handled Fusarium in producing mycelium protein, enhancing its core competitiveness in the international market[18] Operating Costs and Expenses - Total operating costs for the current period were approximately ¥862.33 million, a decrease from ¥1,077.53 million in the previous period, representing a reduction of about 20%[25] - Research and development expenses were approximately ¥44.10 million, down from ¥54.88 million, indicating a reduction of about 19.5%[25] - The company reported a decrease in sales revenue from services, with cash received from sales amounting to ¥572.72 million, down from ¥694.55 million, a decline of approximately 17.5%[28] Investment Activities - The company experienced a 46.47% increase in cash outflows from investing activities, totaling -¥192,721,538.58[9] - The company recorded a 259.60% increase in non-operating income, amounting to ¥1,379,336.30, due to increased disposal of scrapped assets[9]